Brianna Kozemzak, REU Class of 2016, named recipient of the NSF Graduate Research Fellowship Program

Brianna Kozemzak of Saint Mary’s College, Notre Dame, IN receives The National Science Foundation Graduate Research Fellowship Program.  The NSF Graduate Research Fellowship Program (GRFP) helps ensure the vitality of the human resource base of science and engineering in the United States and reinforces its diversity. The program recognizes and supports outstanding graduate students in NSF-supported science, technology, engineering, and mathematics disciplines who are pursuing research-based master’s and doctoral degrees at accredited United States institutions. Fellows benefit from a three-year annual stipend of $34,000 along with a $12,000 cost of education allowance for tuition and fees (paid to the institution), opportunities for international research and professional development, and the freedom to conduct their own research at any accredited U.S. institution of graduate education they choose.

For more information, please visit the following website:

Anna Konstorum receives Ruth L. Kirschstein National Research Service Award (NRSA) Individual Posdoctoral Fellowship (Parent F32)

Anna Konstorum, a postdoctoral fellow of Dr. Reinhard Laubenbacher’s research group at Center for Quantitative Medicine, has been awarded a F32 Postdoctoral Fellowship by the National Cancer Institute (NCI) of the NIH.  Konstorum, Anna 10-23-15 JGelineau #15

The project titled ‘Multiscale modeling of synergistic T cell activation for cancer immunotherapy”.

The Sponsor is Dr. Reinhard Laubenbacher of Center of Quantitative Medicine, Co-Sponsor is Dr. Anthony Vella of the Department of Immunology, and Collaborator is Dr. Adam Adler of the Department of Immunology.

Dr. Anna Konstorum will develop both intracellular and multiscale mathematical and computational models of combined agonist stimulation of T cell costimulatory receptors OX40 (CD137) and 4-1BB (CD134).  The models will be used to decipher the critical mechanisms and scales underlying the experimentally observed synergistic behavior of these two agonists on CD8+ T cell activation, and thus will aide in the development of a quantitative platform from which to examine multiscale drug synergy for application to cancer immunotherapy.